Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.
about
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesisFeasibility of MRI-only treatment planning for proton therapy in brain and prostate cancers: Dose calculation accuracy in substitute CT images.Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.Recurrence prediction in oral cancers: a serum Raman spectroscopy study.Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine ModelOncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.Prostate brachytherapy in Ghana: our initial experience.Special issue on current challenges and future directions in monitoring responses after treatment of primary cancerAdjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line.MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling.Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment.Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.HMGN5 knockdown sensitizes prostate cancer cells to ionizing radiation.The context of prostate cancer genomics in personalized medicine.TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer.Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies.Recent Advances in the Generation of Antibody-Nanomaterial Conjugates.Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy.Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer.The prostate cancer focal therapy.Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men
P2860
Q27320669-4C1790A3-17EE-4CE3-A59C-D37B1BB444DBQ31119375-DAD15C9A-ACB3-456C-9C77-326654CB6EEDQ33711641-2C6A5A73-7F5D-4C9D-9636-D0095A27E2AFQ35221554-907F8AFA-11D3-4EBB-99A8-8BB62B4A7F10Q35548856-04FC31CE-BAA0-48AC-8931-57CB2E8EB830Q36184480-15D1A2A3-857D-41A0-9AB0-E4BBE1D42AC9Q36710972-04CFF95A-5EBF-4C3E-A915-A305E656073DQ37424403-627359A1-1DD8-4E43-8346-27C22C2A9DE1Q37435175-E7A92710-2620-4976-ADBC-0888EBF2DC16Q38699141-C028B232-9B71-4B15-AD35-314503AD7D12Q38760586-354060F3-DE73-4AE5-9EDA-43511A9904EBQ38782227-FBA79669-C0DC-48FB-B4A5-5E133CE02A95Q38790667-667E6F65-8F2B-4781-80B0-5C8986C4A685Q38824756-98E52DFC-13B9-4D00-8C1D-A10635235C75Q38846889-11CECC30-BACE-4645-A5BD-20B993ACDF77Q38939387-D6E318E0-A672-4535-B021-8780892469CCQ38940292-21E0B948-BC4C-45DC-AF50-BDDF6536A885Q38948744-0A5F32AF-607B-4063-9ADB-393A06912DACQ41839243-74540206-CFBD-4FCB-A58D-DE671082E5B9Q42065026-4E24278A-6B5B-4187-B5C3-AF21577E6CB9Q44528110-29943EE4-E587-47ED-8F05-82E0E63B3656Q47554623-469A3100-23EC-40A1-A3ED-C8505540E235Q47725919-1116364D-81CA-4D03-9223-FD2BCD8FF233Q50203117-C251C2F4-9B89-4661-B15D-5BC48C45F246Q53692348-1D07E751-B2B8-4227-954D-819258748021Q54996559-A3138A2D-7157-4968-87FF-35AD6AE20F25Q57112724-F261689B-E9A4-4F72-9DAC-7EA86F8EF5E2Q58752317-81E35BCC-674B-4BC2-A2A6-5953B86CE803
P2860
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current approaches, challenges ...... t response in prostate cancer.
@en
Current approaches, challenges ...... t response in prostate cancer.
@nl
type
label
Current approaches, challenges ...... t response in prostate cancer.
@en
Current approaches, challenges ...... t response in prostate cancer.
@nl
prefLabel
Current approaches, challenges ...... t response in prostate cancer.
@en
Current approaches, challenges ...... t response in prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Current approaches, challenges ...... nt response in prostate cancer
@en
P2093
A Stojadinovic
T J Wallace
P2860
P356
10.7150/JCA.7709
P577
2014-01-01T00:00:00Z